DQP-997-74 (compound 2i) is a selective negative allosteric modulator of N-methyl-d-aspartate receptor (NMDAR) , specifically targeting GluN2C/D ( IC 50 : 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases.
Products | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Alzheimer's Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > iGluR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.